Marken Launches Solo For Management of Clinical Trials Distribution
Marken announced the launch of Solo™, their proprietary web based system used to manage the regulatory, inventory, and operational supply chain complexities of clinical trials. The system, which has been developed exclusively for Marken, is designed to manage all aspects of Marken’s global depot network including: receipt of clinical supplies and kits, dispatches, returns, warehouse movements, and QA releases. Solo™ is a secure, validated*, web-based system which is fully accessible to Marken’s clients on a 24/7 basis from any location in the world. Additionally, Marken has designed Solo™ to integrate with multiple client-directed IXR (Interactive Reporting) systems.
“We are pleased to offer this new system to our growing number of pharmaceutical clients”, said Frank Wright, Interim President, Clinical Trials Distribution at Marken.
“Solo is fit for purpose application which incorporates all of our client’s requirements for remote storage and distribution of their clinical trial supplies. We are also excited to be launching Solo as we manage an increasing number of depots around the world”. Solo™ is purpose-built to allow a high degree of customization supporting the dynamic needs of Marken’s pharmaceutical client base. The system is being launched just as Marken is opening its third fully owned and staffed depot facility in Buenos Aires, Argentina.
*validated in accordance with 21 CFR part 11
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
